Clinical Trial Update: ANRS HC20 Effectiveness of an Optimized Anti HCV PegIFN-alpha2a + Ribavirin on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and Co-infected With HIV [Phase 2]

View source ↗

Summary

A Phase 2 trial assessed an optimized pegylated interferon alfa-2a plus ribavirin regimen for sustained virological response in Hepatitis C genotype 1 and 4 non…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: ANRS, Emerging Infectious Diseases | Conditions: Hepatitis | Phase 2 | Status: COMPLETED